Generation of human myogenic progenitors from pluripotent stem cells for in vivo regeneration

Research output: Contribution to journalReview articlepeer-review

3 Scopus citations


Muscular dystrophy encompasses a large number of heterogeneous genetic disorders characterized by progressive and devastating muscle wasting. Cell-based replacement strategies aimed at promoting skeletal muscle regeneration represent a candidate therapeutic approach to treat muscular dystrophies. Due to the difficulties of obtaining large numbers of stem cells from a muscle biopsy as well as expanding these in vitro, pluripotent stem cells (PSCs) represent an attractive cell source for the generation of myogenic progenitors, given that PSCs can repeatedly produce large amounts of lineage-specific tissue, representing an unlimited source of cells for therapy. In this review, we focus on the progress to date on different methods for the generation of human PSC-derived myogenic progenitor cells, their regenerative capabilities upon transplantation, their potential for allogeneic and autologous transplantation, as well as the specific challenges to be considered for future therapeutic applications.

Original languageEnglish (US)
Article number406
JournalCellular and Molecular Life Sciences
Issue number8
StatePublished - Aug 2022

Bibliographical note

Funding Information:
This project was supported by funds from the NIH-NIAMS, Grants R01 AR071439, AR078571, and AR078624 (RCRP).

Publisher Copyright:
© 2022, The Author(s).


  • Human myogenic progenitors
  • In vivo regeneration
  • Muscular dystrophy
  • Pluripotent stem cells
  • Transgene-dependent
  • Transgene-free

PubMed: MeSH publication types

  • Journal Article
  • Review


Dive into the research topics of 'Generation of human myogenic progenitors from pluripotent stem cells for in vivo regeneration'. Together they form a unique fingerprint.

Cite this